Mitomycin lung toxicity: Acute and chronic phases

Scott Heitaka Okuno, Stephen Frytak

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Pulmonary toxicity is a rare but well described side effect of mitomycin C (MMC). We describe 14 cases of MMC pulmonary toxicity that were detected in four clinical trials performed at The Mayo Clinic using MMC-containing regimens for nonsmall cell lung cancer (NSCLC) and by reviewing the charts of patients treated at The Mayo Clinic with MMC-containing regimens for NSCLC from 1976 to 1995. The median age was 61 (range 44-84) years, with an M:F ratio of 1:1. The median number of cycles of MMC to develop toxicity was four (range two to five) with a median cumulative dose of MMC of 29 mg/m2. MMC toxicity occurred despite pre-medication with corticosteroids in 11 patients. At diagnosis of MMC lung toxicity, the median diffusing lung capacity (DLCO) was 9 and PaO2 was 49 mm Hg. Of those having bronchoscopy, four patients had pulmonary histologic changes consistent with lung injury. Two patients had bronchioalveolar lavages that were nondiagnostic. All patients responded initially to corticosteroids, but approximately 40% had progressive pulmonary insufficiency despite high doses of corticosteroids. This chronic, progressive phase of MMC lung toxicity is a largely underestimated sequelae of MMC.

Original languageEnglish (US)
Pages (from-to)282-284
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume20
Issue number3
DOIs
StatePublished - Jun 1997

Fingerprint

Mitomycin
Lung
Adrenal Cortex Hormones
Non-Small Cell Lung Carcinoma
Lung Volume Measurements
Lung Injury
Bronchoscopy
Bronchoalveolar Lavage
Clinical Trials

Keywords

  • Chemotherapy
  • Drug-lung toxicity
  • Lung cancer
  • Mitomycin C

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mitomycin lung toxicity : Acute and chronic phases. / Okuno, Scott Heitaka; Frytak, Stephen.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 20, No. 3, 06.1997, p. 282-284.

Research output: Contribution to journalArticle

@article{a98f5e4b961d4cbe8481cf4ceb428f9e,
title = "Mitomycin lung toxicity: Acute and chronic phases",
abstract = "Pulmonary toxicity is a rare but well described side effect of mitomycin C (MMC). We describe 14 cases of MMC pulmonary toxicity that were detected in four clinical trials performed at The Mayo Clinic using MMC-containing regimens for nonsmall cell lung cancer (NSCLC) and by reviewing the charts of patients treated at The Mayo Clinic with MMC-containing regimens for NSCLC from 1976 to 1995. The median age was 61 (range 44-84) years, with an M:F ratio of 1:1. The median number of cycles of MMC to develop toxicity was four (range two to five) with a median cumulative dose of MMC of 29 mg/m2. MMC toxicity occurred despite pre-medication with corticosteroids in 11 patients. At diagnosis of MMC lung toxicity, the median diffusing lung capacity (DLCO) was 9 and PaO2 was 49 mm Hg. Of those having bronchoscopy, four patients had pulmonary histologic changes consistent with lung injury. Two patients had bronchioalveolar lavages that were nondiagnostic. All patients responded initially to corticosteroids, but approximately 40{\%} had progressive pulmonary insufficiency despite high doses of corticosteroids. This chronic, progressive phase of MMC lung toxicity is a largely underestimated sequelae of MMC.",
keywords = "Chemotherapy, Drug-lung toxicity, Lung cancer, Mitomycin C",
author = "Okuno, {Scott Heitaka} and Stephen Frytak",
year = "1997",
month = "6",
doi = "10.1097/00000421-199706000-00015",
language = "English (US)",
volume = "20",
pages = "282--284",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Mitomycin lung toxicity

T2 - Acute and chronic phases

AU - Okuno, Scott Heitaka

AU - Frytak, Stephen

PY - 1997/6

Y1 - 1997/6

N2 - Pulmonary toxicity is a rare but well described side effect of mitomycin C (MMC). We describe 14 cases of MMC pulmonary toxicity that were detected in four clinical trials performed at The Mayo Clinic using MMC-containing regimens for nonsmall cell lung cancer (NSCLC) and by reviewing the charts of patients treated at The Mayo Clinic with MMC-containing regimens for NSCLC from 1976 to 1995. The median age was 61 (range 44-84) years, with an M:F ratio of 1:1. The median number of cycles of MMC to develop toxicity was four (range two to five) with a median cumulative dose of MMC of 29 mg/m2. MMC toxicity occurred despite pre-medication with corticosteroids in 11 patients. At diagnosis of MMC lung toxicity, the median diffusing lung capacity (DLCO) was 9 and PaO2 was 49 mm Hg. Of those having bronchoscopy, four patients had pulmonary histologic changes consistent with lung injury. Two patients had bronchioalveolar lavages that were nondiagnostic. All patients responded initially to corticosteroids, but approximately 40% had progressive pulmonary insufficiency despite high doses of corticosteroids. This chronic, progressive phase of MMC lung toxicity is a largely underestimated sequelae of MMC.

AB - Pulmonary toxicity is a rare but well described side effect of mitomycin C (MMC). We describe 14 cases of MMC pulmonary toxicity that were detected in four clinical trials performed at The Mayo Clinic using MMC-containing regimens for nonsmall cell lung cancer (NSCLC) and by reviewing the charts of patients treated at The Mayo Clinic with MMC-containing regimens for NSCLC from 1976 to 1995. The median age was 61 (range 44-84) years, with an M:F ratio of 1:1. The median number of cycles of MMC to develop toxicity was four (range two to five) with a median cumulative dose of MMC of 29 mg/m2. MMC toxicity occurred despite pre-medication with corticosteroids in 11 patients. At diagnosis of MMC lung toxicity, the median diffusing lung capacity (DLCO) was 9 and PaO2 was 49 mm Hg. Of those having bronchoscopy, four patients had pulmonary histologic changes consistent with lung injury. Two patients had bronchioalveolar lavages that were nondiagnostic. All patients responded initially to corticosteroids, but approximately 40% had progressive pulmonary insufficiency despite high doses of corticosteroids. This chronic, progressive phase of MMC lung toxicity is a largely underestimated sequelae of MMC.

KW - Chemotherapy

KW - Drug-lung toxicity

KW - Lung cancer

KW - Mitomycin C

UR - http://www.scopus.com/inward/record.url?scp=0031007223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031007223&partnerID=8YFLogxK

U2 - 10.1097/00000421-199706000-00015

DO - 10.1097/00000421-199706000-00015

M3 - Article

C2 - 9167754

AN - SCOPUS:0031007223

VL - 20

SP - 282

EP - 284

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 3

ER -